NCT03212235

Hypofractionated Radiation Therapy for Glioblastoma

Hypofractionated Radiation Therapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 58 (estimated)
• Sponsor: Instituto do Cancer do Estado de São Paulo · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Notwithstanding major improvements in treatment modalities, the prognosis of patients with glioblastoma is poor. Hypofractionated radiation therapy as an alternative of the standard 6-week regimen could be an attractive approach as an effort to prevent tumor cell repopulation and reduction the total treatment period promoting patient comfort and convenience.

Conditions

• Glioblastoma Multiforme

Interventions

Type	Name	Description
RADIATION	Hypofractionated radiation therapy	Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)

Timeline

• Start date: 2017-06-05
• Primary completion: 2019-06-01
• Completion: 2020-06-01
• First posted: 2017-07-11
• Last updated: 2017-07-11

Locations

1 site across 1 country: Brazil